Related Experiment Videos
Glucocorticoids and acute lung injury
1Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Critical Care Medicine
|April 12, 2003
Summary
High-dose glucocorticoids are ineffective for early ARDS and sepsis. Moderate doses may benefit late ARDS, while some sepsis patients with relative adrenal insufficiency benefit from replacement therapy.
Area of Science:
- Critical care medicine
- Endocrinology
- Immunology
Background:
- Hypothalamic-pituitary-adrenal (HPA) axis activation is a key anti-inflammatory response in critical illness.
- Glucocorticoids modulate immune responses, support vascular tone, and possess antifibrotic properties.
Purpose of the Study:
- To describe HPA activation and glucocorticoid roles in critical illness.
- To review clinical trials on glucocorticoid therapy in ARDS and sepsis.
Main Methods:
- Literature review (1963-present)
- Analysis of clinical trials and meta-analyses.
Main Results:
- High-dose, short-course glucocorticoids show no benefit or harm in early ARDS and sepsis.
- Late, moderate-dose glucocorticoids may benefit ARDS.
- Some sepsis patients with relative adrenal insufficiency improve with replacement therapy.
Conclusions:
- High-dose glucocorticoids are not recommended for early ARDS or sepsis.
- Further research is needed on relative adrenal insufficiency in acute lung injury and its impact on ARDS outcomes.